To provide paid family and medical leave to Federal employees, and for other purposes.
Summary
HR9261, a bill to provide paid family and medical leave to Federal employees, has been introduced and referred to three committees. It is in the earliest legislative stage with no funding specified and only two cosponsors. There is no direct market impact on publicly traded companies identified at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9261 is a bill affecting only Federal employees, not private sector companies or investors.
- 2.The bill is in the earliest legislative stage with no funding amount and only two cosponsors.
- 3.No publicly traded company has a causal chain to this bill — no tickers are affected.
Market Implications
No market implications. This bill does not affect any revenue stream, cost structure, or competitive position of any publicly traded company. Investors should await significant legislative progress (committee markups, amendments, funding provisions) before any market analysis is warranted.
Full Analysis
-
On 2026-06-11, Rep. Beyer (D-VA-8) introduced HR9261 in the 119th Congress. The bill was referred to the Committees on Oversight and Government Reform, Veterans' Affairs, and House Administration. It remains in early stage—no hearings, markup, or floor votes have occurred.
-
The bill authorizes no specific dollar amount. It proposes a policy mandate for paid leave for Federal employees. No appropriations are attached. Authorization bills of this nature would require a separate appropriations bill to fund any leave benefits. There is no procurement, contract, or grant mechanism tied to private companies.
-
Because this bill exclusively covers Federal employees, it does not directly affect the revenue streams of publicly traded companies. The affected sector is Healthcare broadly, but only because paid leave can indirectly affect workforce health costs—no specific company exposure is created.
-
No real market data is provided for any ticker specific to this bill. The financial data provided (AbbVie, Abbott, HCA, JNJ, Lilly, Medtronic, Merck, Pfizer, UnitedHealth) does not establish a causal link to this legislation. These companies are not obligated by or beneficiaries of this Federal employee leave policy.
-
Remaining steps: committee hearings in at least three committees, potential markup, House floor vote, Senate companion introduction and passage, Presidential action. No timeline exists at this stage. The bill has very low momentum with only 2 cosponsors and no Senate companion.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.